Neurogene Inc. (NASDAQ:NGNE) Earns a Consensus "Buy" Rating from Brokerage Firms

2 min read | January 31, 2025 06:23 PM AEDT | By Team Kalkine Media

Neurogene Inc. (NASDAQ:NGNE) Earns a Consensus

Insider Transactions and Strategic Acquisitions

Recent insider transactions further bolster confidence in Neurogene's potential. Major shareholder Samsara Biocapital Gp, Llc expanded its holdings by acquiring 48,770 shares, remaining optimistic about the company's future. Similarly, Christine Mikail Cvijic, the CFO, made a significant purchase of 24,000 shares, marking a noteworthy increase in insider ownership. These insider activities underscore the bullish sentiment amongst those closest to the company.

Institutional Investment Growth

Institutional investors have also demonstrated increased interest in Neurogene. Throughout recent quarters, there have been notable changes in positions on Neurogene shares, suggesting a strategic bet on the company's potential. For instance, Rhumbline Advisers increased its stake by 9.2% in the fourth quarter, showcasing a growing confidence among institutional holders.

Other major players such as Barclays PLC and Jane Street Group LLC have either initiated or significantly increased their presence in the company. As a result, institutional investors currently own an impressive 52.37% of Neurogene's stocks, further indicating the market's positive outlook on its future performance.

About Neurogene

Neurogene Inc. specializes in developing genetic medicines targeted at rare neurological diseases. The company's leading product candidates, NGN-401 and NGN-101, are generating interest as they advance through Phase 1/2 clinical trials. These initiatives are critical in exploring potential treatments for Rett syndrome and CLN5 Batten disease, offering hope for better therapeutic solutions in these challenging areas.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.